86. Pulmonary arterial hypertension Clinical trials / Disease details


Clinical trials : 1,181 Drugs : 701 - (DrugBank : 126) / Drug target genes : 105 - Drug target pathways : 192

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-003978-41-Outside-EU/EEA
(EUCTR)
13/10/2016Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial HypertensionA Phase 3, Multi-center, Open label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension Pulmonary arterial hypertension
MedDRA version: 19.0;Level: PT;Classification code 10064911;Term: Pulmonary arterial hypertension;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Revatio 10 mg/ml powder for oral suspension
Product Name: Revatio POS
Product Code: G04BE03
INN or Proposed INN: 171
Other descriptive name: SILDENAFIL CITRATE
Trade Name: Revatio 20 mg film coated tablets
Product Name: Revatio Tablets
Product Code: G04BE03
INN or Proposed INN: 171
Other descriptive name: SILDENAFIL CITRATE
Pfizer, Inc.NULLNAFemale: yes
Male: yes
6Phase 3Japan